Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA)
Health Care · Biotechnology · US
$12.37
+1.64% today · +11.6% 1Y
Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $360.28M and employs 120 people.
Over the last twelve months the share price has gained 11.6%, trading between 10.20 and 17.15.
Tweenvest scores Enanta Pharmaceuticals, Inc. across four factors: quality 43/100, value 63/100, growth 0/100. Its strongest factor is value.
ENTA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $360.28M
- Revenue (TTM)
- $65.26M
- P/E
- —
- EPS
- -2.34
- Dividend yield
- —
- Beta (5Y)
- 0.96
- 52-week high
- $17.15
- 52-week low
- $10.20
- Avg volume (3M)
- —
- Shares outstanding
- 29.13M
- Employees
- 120
- Next earnings
- —
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
- ISIN
- US29251M1062
- Founded
- 1995
- Listed since
- Mar 21, 2013
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Opus Genetics, Inc.NasdaqCM: IRD | $366.89M | $4.41 | +0.68% |
| BioDlink International Company LimitedSEHK: 1875 | $366.35M | HK$3.72 | -3.38% |
| Inhibikase Therapeutics, Inc.NasdaqCM: IKT | $364.15M | $1.94 | -3.00% |
| Emergent BioSolutions Inc.NYSE: EBS | $362.50M | $7.07 | +1.73% |
| ProKidney Corp.NasdaqCM: PROK | $359.35M | $1.57 | -8.72% |
| ROKIT Healthcare Inc.KOSDAQ: A376900 | $357.79M | ₩27,750.00 | -1.25% |
| Fennec Pharmaceuticals Inc.NasdaqCM: FENC | $357.69M | $10.36 | +1.57% |
| Cuorips Inc.TSE: 4894 | $352.47M | ¥6,260.00 | +5.56% |
Figures last refreshed Oct 4, 2026.